On Thursday, Telo Genomics Corp (OTC:TDSGF) announced that the manuscript “Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma” was accepted for publication in the American Journal of Hematology.
The published study included a total of 168 smoldering multiple myeloma patients.
The article describes the results of Telo’s prognostic test for smoldering multiple myeloma (TeloViewSMM).
The results described in the publication demonstrated superior performance characteristics compared to other oncology prognostic tests or scoring systems in smoldering multiple ...